Other disorders of intestinal carbohydrate absorption. Glucose-galactose malabsorption
Conditions
Interventions
Intervention 1: Control group: placebo tablet for 3 months. Intervention 2: Intervention group: 1000 IU/daily vitamin D for 3 months.
Control group: placebo tablet for 3 months
Intervention group: 1000 IU/daily vitamin D for 3 months
Sponsors
Vice chancellor for research, Urmia University of Medical sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: prediabetic adults; vitamin D Insufficient; 30-70 age group Exclusion criteria: any diseases which may affect vitamin D metabolism and status or blood glucose control; such as type 1 or type 2 diabetes; kidney diseases; sarcoidosis; cancers; hyperparathyroidism; heart diseases; liver diseases; pregnant and lactating women; poly cystic ovarian syndrome; hypercalcemia; inflammatory bowel disease; cystic fibrosis; gastric bypass surgery; cholecystectomy; serious pulmonary diseases; patients took anti - convulsants; digoxin; contraceptives; orlistat and vitamin D supplements within the last three months; smoking and drinking alcohol; patients who changed their lifestyle and dietary habits during the intervention period; having the threshold serum 25(OH)D of either D3 150 nmol/ml; patients without informed consent and those who were taking less than 90% of the supplements given to take during the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood sugar (FBS). Timepoint: before intervention, 3 months after intervention. Method of measurement: mg/dl.;Glycated hemoglobin (HbA1c). Timepoint: before intervention, 3 months after intervention. Method of measurement: %, Gama.;Serum insulin. Timepoint: before intervention, 3 months after intervention. Method of measurement: mg/dl.;Percentage body fat mass. Timepoint: before intervention, 3 months after intervention. Method of measurement: %, kaliper.;Serum 25(OH)D. Timepoint: before intervention, 3 months after intervention. Method of measurement: ng/ml.;Homeostasis model assessment of insulin resistance (HOMA-IR). Timepoint: before intervention, 3 months after intervention. Method of measurement: FBS*Insulin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Daily sun exposure. Timepoint: before intervention, 3 months after intervention. Method of measurement: hour.;Waist Circumference. Timepoint: before intervention, 3 months after intervention. Method of measurement: cm.;Body Mass Index (BMI). Timepoint: before intervention, 3 months after intervention. Method of measurement: kg/m2. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Rasoul Zarrin
Urmia University of Medical Sciences
Outcome results
None listed